Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.
Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...
Zacks Investment Research on MSN6d
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma DrugRegeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.
MedPage Today on MSN7d
The Basics of Multiple MyelomaIn spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...
City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...
A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...
A 63-year-old patient with multiple myeloma developed T cell lymphoma in the blood ... analysed the transcriptome of the CAR-T cells to investigate genes and signalling pathways. These methods had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback